Clinical Trial

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of \[177Lu\]Lu-DWJ155 and the safety and imaging properties of \[68Ga\]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction (GEJ) cancer, and bladder cancer.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-24
notable Trial sites expanded: 0 -> 3 locations 2026-06-24
Trial Details
NCT Number NCT07660055
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Enrollment 156 participants
Start Date 2026-06-16
Primary Completion 2032-05-24 (estimated)
Study Completion 2032-05-24 (estimated)
Updated on ClinicalTrials.gov 2026-06-23